Retraction Note: Microglia-dependent synapse loss in type I interferon-mediated lupus (Nature, (2017), 546, 7659, (539-543), 10.1038/nature22821);Microglia-dependent synapse loss in type i interferon-mediated lupus

Nature

Volumn 546, Issue 7659, 2017, Pages 539-543

  Bialas, Allison R ^a   Presumey, Jessy ^a   Das, Abhishek ^a   Van Der Poel, Cees E ^a   Lapchak, Peter H ^a   Mesin, Luka ^b   Victora, Gabriel ^b   Tsokos, George C ^a   Mawrin, Christian ^a,c   Herbst, Ronald ^d   Carroll, Michael C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIFROLUMAB; CD39 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; INTERFERON; RNA; MONOCLONAL ANTIBODY; TRANSCRIPTOME;

ANTIBODY; BRAIN; EXPERIMENTAL STUDY; GENETIC ANALYSIS; MENTAL HEALTH; NERVOUS SYSTEM; NERVOUS SYSTEM DISORDER; RODENT;

ANIMAL MODEL; ARTICLE; CELL LOSS; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; SYNAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BRAIN VASCULITIS; DISEASE MODEL; FEMALE; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; PSYCHOLOGY;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HUMANS; INTERFERON TYPE I; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MICE; MICROGLIA; PHENOTYPE; SIGNAL TRANSDUCTION; SYNAPSES; TRANSCRIPTOME;

EID: 85021080879     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-020-1949-x     Document Type: Erratum

References (39)

1. Popescu, A. & Kao, A. H. Neuropsychiatric systemic lupus erythematosus. Curr. Neuropharmacol. 9, 449-457 (2011).
2. Feinglass, E. J., Arnett, F. C., Dorsch, C. A., Zizic, T. M. & Stevens, M. B. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55, 323-339 (1976).
3. van Dam, A. P. Diagnosis and pathogenesis of CNS lupus. Rheumatol. Int. 11, 1-11 (1991).
4. Hanly, J. G. et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 56, 265-273 (2007).
5. DeGiorgio, L. A. et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189-1193 (2001).
6. Sanna, G. et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30, 985-992 (2003).
7. Furie, R. et al. Anifrolumab, an anti-interferon-receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376-386 (2017).
8. Berland, R. et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25, 429-440 (2006).
9. Das, A. et al. Follicular dendritic cell activation by TLR ligands promotes autoreactive B cell responses. Immunity 46, 106-119 (2017).
10. Lynch, M. A. The multifaceted profile of activated microglia. Mol. Neurobiol. 40, 139-156 (2009).
11. Crupi, R. et al. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol. Psychiatry 67, 558-566 (2010).
12. Mondal, T. K., Saha, S. K., Miller, V. M., Seegal, R. F. & Lawrence, D. A. Autoantibody-mediated neuroinflammation: pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Brain Behav. Immun. 22, 949-959 (2008).
13. Dubois, E. L., Horowitz, R. E., Demopoulos, H. B. & Teplitz, R. NZB/NZW mice as a model of systemic lupus erythematosus. J. Am. Med. Assoc. 195, 285-289 (1966).
14. Baccala, R. et al. Anti-IFN-receptor antibody treatment ameliorates disease in lupus-predisposed mice. J. Immunol. 189, 5976-5984 (2012).
15. Sakic, B. et al. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav. Immun. 6, 265-285 (1992).
16. Goldmann, T. et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 34, 1612-1629 (2015).
17. Crow, Y. J. et al. Mutations in the gene encoding the 3-5 DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat. Genet. 38, 917-920 (2006).
18. Meuwissen, M. E. et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 213, 1163-1174 (2016).
19. Taylor, J. M. et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol. Aging 35, 1012-1023 (2014).
20. Baruch, K. et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89-93 (2014).
21. Kirou, K. A. et al. Coordinate overexpression of interferon-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004).
22. Trysberg, E., Carlsten, H. & Tarkowski, A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 9, 498-503 (2000).
23. Santer, D. M., Yoshio, T., Minota, S., Möller, T. & Elkon, K. B. Potent induction of IFN-and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 182, 1192-1201 (2009).
24. Hickman, S. E. et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896-1905 (2013).
25. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
26. Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705 (2012).
27. Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712-716 (2016).
28. Pan, W., Banks, W. A. & Kastin, A. J. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J. Neuroimmunol. 76, 105-111 (1997).
29. Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164-1178 (2007).
30. Islam, S. et al. Quantitative single-cell RNA-seq with unique molecular identifiers. Nat. Methods 11, 163-166 (2014).
31. Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
32. Chatterjee, P. et al. Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur. J. Immunol. 43, 2441-2450 (2013).
33. Tucker, K. L., Meyer, M. & Barde, Y.-A. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 4, 29-37 (2001).
34. Armulik, A. et al. Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010).
35. Ben-Zvi, A. et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 509, 507-511 (2014).
36. Schafer, D. P., Lehrman, E. K., Heller, C. T. & Stevens, B. An engulfment assay: a protocol to assess interactions between CNS phagocytes and neurons. J. Vis. Exp. (88) e51482 (2014).
37. Tremblay, M.-È, Lowery, R. L. & Majewska, A. K. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8, e1000527 (2010).
38. Bisht, K. et al. Dark microglia: a new phenotype predominantly associated with pathological states. Glia 64, 826-839 (2016).
39. Mori, S. & Leblond, C. P. Identification of microglia in light and electron microscopy. J. Comp. Neurol. 135, 57-79 (1969).